Vertex Pharmaceuticals Incorporated Stock price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
411.4 USD +0.91% Intraday chart for Vertex Pharmaceuticals Incorporated -0.75% +1.10%
Sales 2024 * 10.73B Sales 2025 * 11.74B Capitalization 105B
Net income 2024 * 3.9B Net income 2025 * 4.5B EV / Sales 2024 * 8.22 x
Net cash position 2024 * 17.11B Net cash position 2025 * 21.54B EV / Sales 2025 * 7.14 x
P/E ratio 2024 *
27.1 x
P/E ratio 2025 *
23.6 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.66%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Vertex Pharmaceuticals Incorporated Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM
Transcript : Vertex Pharmaceuticals Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,142,974, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $506,546, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,519,637, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Gets Positive Opinion for Kalydeco From European Medicines Agency to Treat Cystic Fibrosis MT
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants DJ
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older CI
Prices for new US drugs rose 35% in 2023, more than the previous year RE
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,776,528, According to a Recent SEC Filing MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target MT
(OFFICIAL)-Latigo Biotherapeutics raises $135 mln for non-opioid painkillers RE
Vertex Pharmaceuticals Insider Sold Shares Worth $727,822, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,804,931, According to a Recent SEC Filing MT
More news
1 day+0.91%
1 week-0.53%
Current month-2.22%
1 month-2.56%
3 months+0.17%
6 months+17.91%
Current year+1.10%
More quotes
1 week
406.97
Extreme 406.97
416.11
1 month
406.97
Extreme 406.97
437.00
Current year
403.43
Extreme 403.43
448.40
1 year
296.09
Extreme 296.09
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
163.68
Extreme 163.681
448.40
10 years
59.79
Extreme 59.79
448.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 17-01-31
Chairman 68 09-07-07
Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Director/Board Member 68 17-06-07
Chairman 68 09-07-07
Director/Board Member 64 97-12-31
More insiders
Date Price Change Volume
24-03-18 411.4 +0.91% 926,467
24-03-15 407.7 -0.26% 1,905,702
24-03-14 408.8 -1.07% 1,031,358
24-03-13 413.2 +0.18% 764,712
24-03-12 412.4 -0.49% 888,995

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (63.8%), Europe (30.3%) and other (5.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
411.4 USD
Average target price
459.8 USD
Spread / Average Target
+11.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Vertex Pharmaceuticals Incorporated - Nasdaq